NICE National Institute for Health and Care Excellence

Technology Advisory Committee D Interests Register

Topic: Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Will Sullivan	Committee Member	Direct - Financial	Will is part of a team providing ongoing health economic consultancy services to Eisai Canada concerning the technology lemborexant to treat insomnia. Will is part of a team providing ongoing health economic consultancy services to Novartis concerning the technology asciminib to treat newly diagnosed chronic myelogenous leukaemia.	06/06/2024 15/01/2025	It was agreed that Will's declaration would not prevent him from participating in discussions on this appraisal.
Professor David Meads	Committee Member	Direct – non-financial professional	Professor Meads' employer, the University of Leeds, has received funding from Takeda for research in an unrelated area.	13/06/2024 15/01/2025	It was agreed that Professor Meads' declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Matthew Bradley	Committee Member	Direct - Financial	Dr Bradley's company is co-developing latozinemab (AL001), an investigational human monoclonal antibody designed to modulate progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. Latozinemab is currently in Ph3 development for frontotemporal dementia with a progranulin gene mutation (FTD-GRN).	10/06/2024	It was agreed that Dr Bradley's declaration would prevent him from participating in discussions on this appraisal.
Dr Jacoline Bouvy	NICE Programme Director - Medicines Evaluation	Direct – Professional	Dr Bouvy is co-author of the Landeiro et al 2020 paper which is referenced in the company submission.	03/07/2024 15/01/2025	It was agreed that Dr Bouvy's declaration would not prevent her from participating in discussions on this appraisal.
Professor Nick Fox	Clinical Expert	Direct - Professional	Professor Fox has served on advisory boards, provided consultancy services, or spoken at meetings for several pharmaceutical companies including Eisai, Eli Lilly, Biogen, Ionis and Roche for which	11/12/2024 15/01/2025	It was agreed that Professor Fox's declaration would not prevent him from providing

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			his employer, UCL, received payments. The focus was on clinical trials in Alzheimer's disease. Professor Fox is a member and former Chair of the Alzheimer's Society Research Strategy Council, which is his nominating organisation.		expert advice to the committee.
Dr Tomas Welsh	Clinical Expert	Direct - Professional	Dr Welsh is the site PI for the TRAILBLAZER-5 study (donanemab). Dr Welsh is Research and Medical Director of The Research Institute for the Care of Older People (RICE), Bath, UK, which runs a mixture of commercial and non-commercial research activity. Commercial research projects run in the Institute have been funded by: Lilly, Roche, Biogen, Eisai, Janssen, AC Immune, Novo Nordisk, Pfizer, Elan, Immunobrain, Actinogen, and Julius Clinical. RICE is a member of the	03/07/2024 29/01/2024 15/01/2025	It was agreed that Dr Welsh's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			European Alzheimer's Disease Consortium (EADC)		
Peter Almond	Patient Expert	Direct - Personal	Peter has been a participant in a donanemab trial since 2021.	17/01/2024	It was agreed that Peter's declaration would not prevent him from providing expert advice to the committee.
Dr Jeremy Isaacs	Commissioning Expert	Direct - financial	Dr Isaacs has received conference expenses and consultancy fees (paid to his institution) from Roche, a speaker's fee (paid to his institution) from Biogen and payment from Nestle Health Science for membership of a clinical trial academic steering committee. Dr Isaacs has no financial relationship with Eli Lilly.	25/06/2024 15/01/2025	It was agreed that Dr Isaacs' declaration would not prevent him from providing expert advice to the committee.
Dr Jeremy Isaacs	Commissioning Expert	Direct – non-financial	Dr Isaacs has been a clinical triallist on commercial clinical trials of amyloid-lowering drugs in Alzheimer's disease sponsored by Roche. A clinical trial of donanemab in Alzheimer's disease sponsored by	25/06/2024 15/01/2025	It was agreed that Dr Isaacs' declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Eli Lilly is currently in set up at Dr Isaac's institution (St George's University Hospitals NHS Foundation Trust) with him as the site principal investigator. Dr Isaacs has written an opinion piece in a journal about amyloid-lowering therapies, although this predated the publication of the pivotal phase 3 donanemab trial under consideration here: Alzheimer's disease: Have we opened the Golden Gate to disease-modifying therapy? - ScienceDirect Dr Isaacs is an author on a paper estimating potential demand for Alzheimer's DMTs in the UK: Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK | The British Journal of Psychiatry | Cambridge Core		
Dr Jeremy Isaacs	Commissioning Expert	Indirect – professional	Dr Isaacs' partner is a Chair of one of the NICE TA appeal committees.	25/06/2024 15/01/2025	It was agreed that Dr Isaacs' declaration would not prevent him from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					providing expert advice to the committee.